Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen‐induced pulmonary inflammation in mice

Abstract

Background

Accumulation of activated eosinophils in tissue is a hallmark of allergic inflammation. The endocannabinoid 2‐arachidonoylglycerol (2‐ AG) has been proposed to elicit eosinophil migration in a CB ₂ receptor/G _i/o‐dependent manner. However, it has been claimed recently that this process may also involve other mechanisms such as cytokine priming and the metabolism of 2‐ AG into eicosanoids. Here, we explored the direct contribution of specific CB ₂ receptor activation to human and mouse eosinophil effector function in vitro and in vivo.

Methods

In vitro studies including CB ₂ expression, adhesion and migratory responsiveness, respiratory burst, degranulation, and calcium mobilization were conducted in human peripheral blood eosinophils and mouse bone marrow‐derived eosinophils. Allergic airway inflammation was assessed in mouse models of acute OVA‐induced asthma and directed eosinophil migration.

Results

CB ₂ expression was significantly higher in eosinophils from symptomatic allergic donors. The selective CB ₂ receptor agonist JWH‐133 induced a moderate migratory response in eosinophils. However, short‐term exposure to JWH‐133 potently enhanced chemoattractant‐induced eosinophil shape change, chemotaxis, CD11b surface expression, and adhesion as well as production of reactive oxygen species. Receptor specificity of the observed effects was confirmed in eosinophils from CB ₂ knockout mice and by using the selective CB ₂ antagonist SR144528. Of note, systemic application of JWH‐133 clearly primed eosinophil‐directed migration in vivo and aggravated both AHR and eosinophil influx into the airways in a CB ₂‐specific manner. This effect was completely absent in eosinophil‐deficient ∆dbl GATA mice.

Conclusion

Our data indicate that CB ₂ may directly contribute to the pathogenesis of eosinophil‐driven diseases. Moreover, we provide new insights into the molecular mechanisms underlying the CB ₂‐mediated priming of eosinophils. Hence, antagonism of CB ₂ receptors may represent a novel pharmacological approach for the treatment of allergic inflammation and other eosinophilic disorders.